Why carry out this study?

Many studies reported remarkable cardiovascular efficacy of glucagon-like peptide 1 receptor agonists (GLP-1RAs) in type 2 diabetes mellitus (T2DM), but the differences in cardiovascular efficacy among various subpopulations of patients with T2DM remained unknown.

What were the subpopulation differences in cardiovascular efficacy of long-acting GLP-1RAs among patients with T2DM?

What was learned from the study?

Our studies suggested that the subpopulation differences in cardiovascular efficacy of long-acting GLP-1RAs were insignificant among subpopulations stratified by different influential factors, and only favorable trends were noticed in the subpopulation with established CVD.

Our findings might have implications for the management of long-acting GLP-1RAs treatments across various subpopulations of patients with T2DM, as well as the safety of long-acting GLP-1RAs.